Instead of waiting until advanced disease stages or after other therapies fail, GLP-1s are increasingly being used early, sometimes even at diagnosis
Do not squirt directly onto the lyophilised peptide powder this shears the peptide
Eligibility for weight loss injections typically requires a BMI 30 kg/m or 27 kg/m with at least one weight-related complication (such as hypertension, dyslipidemia, type 2 diabetes, or MASLD)
Plasma donations should always be performed in a qualified facility that utilizes sterilized equipment
Tirzepatide received its first FDA approval in 2022
Wegovy has the strongest cardiovascular evidence of any GLP-1 medication thanks to the SELECT trial, which demonstrated a 20% reduction in major adverse cardiac events (heart attack, stroke, and cardiovascular death) in people with obesity and established heart disease